XNAS · Healthcare · Biotechnology
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -1.17 | -1.34 | -14.53% | $0 | ❌ Miss | -0.93% | +10.90% | — |
| 2026-02-26 | Q4 2025 | -1.11 | -1.03 | +7.21% | $0 | ✅ Beat | -0.58% | +16.38% | +22.65% |
| 2025-11-06 |
| Q3 2025 |
| -1.05 |
| -1.02 |
| +2.86% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-20 | Q4 2024 | -0.92 | -0.84 | +8.70% | $0 | ✅ Beat | -4.64% | -14.74% | -19.21% |
| 2024-11-07 | Q3 2024 | -0.82 | -1.20 | -46.34% | $0 | ❌ Miss | -3.02% | -4.57% | +9.44% |
| 2024-08-14 | Q2 2024 | -1.50 | -4.34 | -189.33% | $0 | ❌ Miss | +5.23% | +1.18% | +12.02% |
Showing last 6 quarters.